**Table 1 Supplement: Max. FEV1 decrease and eNO before and after sc-LCPUFA or placebo supplementation**

|  |  |  |
| --- | --- | --- |
|  | **FEV1** | **eNO** |
| [% pred] | [ppb] |
| **sc-LCPUFA** | **Placebo** | **sc-LCPUFA** | **Placebo** |
| **pre** | **post** | **pre** | **post** | **pre** | **post** | **pre** | **post** |
| **Total** | **Median** | **29.8** | **24.8** | **26.8** | **26.5** | **20.0** | **18.5** | **29.0** | **28.5** |
| 25% percentile | 21.8 | 10.3 | 19.9 | 14.6 | 10.0 | 10.3 | 13.0 | 13.3 |
| 75%percentile | 37.6 | 37.6 | 43.2 | 41.7 | 51.3 | 59.3 | 49.3 | 52.8 |
| **Adult** | **Median** | **29.2** | **26.2** | **23.0** | **26.4** | **20.0** | **16.0** | **29.0** | **23.0** |
| 25% percentile | 21.8 | 10.9 | 20.1 | 15.2 | 9.0 | 9.0 | 11.5 | 12.0 |
| 75%percentile | 35.0 | 33.7 | 38.0 | 32.0 | 62.5 | 69.0 | 45.5 | 39.0 |
| **Children** | **Median** | **30.6** | **20.8** | **32.0** | **26.7** | **21.0** | **19.0** | **26.0** | **38.0** |
| 25% percentile | 21.4 | 7.8 | 19.2 | 9.4 | 10.0 | 13.0 | 16.0 | 13.0 |
| 75%percentile | 45.6 | 44.1 | 44.8 | 48.2 | 52.0 | 51.0 | 57.0 | 66.0 |

% pred, % predicted; ppb, parts per billion.